Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Fotini Vogiatzi; Dorothee Winterberg; Lennart Lenk; Swantje Buchmann; Gunnar Cario; Martin Schrappe; Matthias Peipp; Paulina Richter-Pechanska; Andreas E. Kulozik; Jana Lentes; Anke K. Bergmann; Thomas Valerius; Fabian Simon Frielitz; Christian Kellner; Denis M. Schewe

doi:10.1182/blood.2019000904

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Fotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E. Kulozik, Jana Lentes, Anke K. Bergmann, Thomas Valerius, Fabian Simon Frielitz, Christian Kellner, Denis M. Schewe^*

^*Corresponding author for this work

Institute of Social Medicine and Epidemiology

6 Citations (Scopus)

Original language	English
Journal	Blood
Volume	134
Issue number	8
Pages (from-to)	713-716
Number of pages	4
ISSN	0006-4971
DOIs	https://doi.org/10.1182/blood.2019000904
Publication status	Published - 22.08.2019

Funding

This work was supported by the Deutsche Krebshilfe (grant 70113524) (D.M.S. and C.K.) and the Deutsche José-Carreras Leukämiestiftung (grant DJCLS 17 R/2017) (D.M.S. and C.K.). M.P. is supported by the Deutsche Krebshilfe Mildred-Scheel professorship program. A.K.B. is supported by the Deutsche Forschungsgemeinschaft (BE 6555/1-1).

Research Areas and Centers

Research Area: Center for Population Medicine and Public Health (ZBV)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood.2019000904

Cite this

Vogiatzi, F., Winterberg, D., Lenk, L., Buchmann, S., Cario, G., Schrappe, M., Peipp, M., Richter-Pechanska, P., Kulozik, A. E., Lentes, J., Bergmann, A. K., Valerius, T., Frielitz, F. S., Kellner, C., & Schewe, D. M. (2019). Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood, 134(8), 713-716. https://doi.org/10.1182/blood.2019000904

@article{595d2a9a97004c218a05c1b18b4d472d,

title = "Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia",

author = "Fotini Vogiatzi and Dorothee Winterberg and Lennart Lenk and Swantje Buchmann and Gunnar Cario and Martin Schrappe and Matthias Peipp and Paulina Richter-Pechanska and Kulozik, {Andreas E.} and Jana Lentes and Bergmann, {Anke K.} and Thomas Valerius and Frielitz, {Fabian Simon} and Christian Kellner and Schewe, {Denis M.}",

note = "Funding Information: This work was supported by the Deutsche Krebshilfe (grant 70113524) (D.M.S. and C.K.) and the Deutsche Jos{\'e}-Carreras Leuk{\"a}miestiftung (grant DJCLS 17 R/2017) (D.M.S. and C.K.). M.P. is supported by the Deutsche Krebshilfe Mildred-Scheel professorship program. A.K.B. is supported by the Deutsche Forschungsgemeinschaft (BE 6555/1-1). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = aug,

day = "22",

doi = "10.1182/blood.2019000904",

language = "English",

volume = "134",

pages = "713--716",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "8",

}

Vogiatzi, F, Winterberg, D, Lenk, L, Buchmann, S, Cario, G, Schrappe, M, Peipp, M, Richter-Pechanska, P, Kulozik, AE, Lentes, J, Bergmann, AK, Valerius, T, Frielitz, FS, Kellner, C & Schewe, DM 2019, 'Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia', Blood, vol. 134, no. 8, pp. 713-716. https://doi.org/10.1182/blood.2019000904

TY - JOUR

T1 - Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

AU - Vogiatzi, Fotini

AU - Winterberg, Dorothee

AU - Lenk, Lennart

AU - Buchmann, Swantje

AU - Cario, Gunnar

AU - Schrappe, Martin

AU - Peipp, Matthias

AU - Richter-Pechanska, Paulina

AU - Kulozik, Andreas E.

AU - Lentes, Jana

AU - Bergmann, Anke K.

AU - Valerius, Thomas

AU - Frielitz, Fabian Simon

AU - Kellner, Christian

AU - Schewe, Denis M.

N1 - Funding Information: This work was supported by the Deutsche Krebshilfe (grant 70113524) (D.M.S. and C.K.) and the Deutsche José-Carreras Leukämiestiftung (grant DJCLS 17 R/2017) (D.M.S. and C.K.). M.P. is supported by the Deutsche Krebshilfe Mildred-Scheel professorship program. A.K.B. is supported by the Deutsche Forschungsgemeinschaft (BE 6555/1-1). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/8/22

Y1 - 2019/8/22

UR - http://www.scopus.com/inward/record.url?scp=85071471219&partnerID=8YFLogxK

U2 - 10.1182/blood.2019000904

DO - 10.1182/blood.2019000904

M3 - Letters

C2 - 31311816

AN - SCOPUS:85071471219

SN - 0006-4971

VL - 134

SP - 713

EP - 716

JO - Blood

JF - Blood

IS - 8

ER -

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Funding

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Cite this